We're taking a closer look at Summit Therapeutics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 4.6% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
-
Summit Therapeutics has moved 404.8% over the last year compared to 23.6% for the S&P 500 -- a difference of 381.1%
-
SMMT has an average analyst rating of buy and is -40.93% away from its mean target price of $32.22 per share
-
Its trailing 12 month earnings per share (EPS) is $-0.23
-
Summit Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -82.7 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $-0.38 and its forward P/E ratio is -50.1
-
The company has a Price to Book (P/B) ratio of 32.04 in contrast to the S&P 500's average ratio of 4.74
-
Summit Therapeutics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
-
Summit Therapeutics has on average reported free cash flows of $-49658500.0 over the last four years, during which time they have grown by an an average of -28.2%
